Fistula - Medium 1-3 Biopsy cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Fistulas are commonly pathological and can result from: Infections\n, Inflammatory conditions (e.g., Crohn’s disease), Surgery or trauma, Malignancy or radiation damage

₹399₹1,000

60% OFF

Fistula - Medium 1-3 cm Biopsy

Why is it done?
- To obtain tissue samples from a fistula tract measuring 1-3 centimeters in length for histopathological examination and diagnosis
- To identify the underlying etiology of the fistula, including infectious agents, inflammatory bowel disease, malignancy, or other pathological processes
- To determine the presence of granulomas, which may suggest tuberculosis, sarcoidosis, or fungal infections
- To evaluate for malignant transformation or suspicious lesions within the fistula tract
- To guide treatment decisions and determine if surgical intervention is necessary
- Typically performed when a fistula has persisted longer than expected or when diagnosis is clinically uncertain
Normal Range
- Normal results: Absence of granulomas, malignant cells, or pathogenic organisms
- Tissue composition: Normal fibrous tissue, minimal inflammation, or benign reactive changes
- Normal interpretation: Benign fistula, likely traumatic, post-surgical, or simple infection-related in nature
- Units: Microscopic tissue architecture is evaluated qualitatively using standard histological staining (H&E, special stains as indicated)
- Specimen adequacy: Sample should contain sufficient tissue material (typically >3mm) for definitive interpretation
Interpretation
- Granulomatous inflammation: Suggests tuberculosis, sarcoidosis, histoplasmosis, coccidioidomycosis, or atypical mycobacterial infection; may also indicate Crohn's disease in GI fistulas
- Acute inflammation with suppuration: Indicates active bacterial infection; culture results may guide antibiotic therapy
- Chronic inflammation with fibrosis: Consistent with long-standing fistula, post-traumatic or post-surgical origin
- Malignant cells or squamous cell carcinoma: Indicates malignant transformation of chronic fistula; requires urgent surgical intervention and oncologic consultation
- Foreign material or polarizable substances: Suggests foreign body reaction or material-induced fistula formation
- Special stain findings: Acid-fast organisms (tuberculosis), fungal elements, or specific organisms guide targeted treatment
- Inadequate specimen: If tissue sample is insufficient or poorly preserved, repeat biopsy may be necessary for definitive diagnosis
Associated Organs
- Primary organs: Skin and subcutaneous tissues, anal/rectal region (anorectal fistulas), perianal area, oral cavity, or areas of chronic drainage
- Associated conditions - Infectious: Tuberculosis, atypical mycobacterial infections, fungal infections, actinomycosis, and chronic bacterial infections
- Associated conditions - Inflammatory: Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and other inflammatory bowel conditions
- Associated conditions - Malignant: Squamous cell carcinoma, basal cell carcinoma, and other malignancies arising from chronic fistula tracts
- Associated conditions - Other: Pilonidal sinus disease, branchial cleft cysts, thyroglossal duct cysts, and post-surgical/post-traumatic fistulas
- Potential complications: Chronic infection, abscess formation, systemic infection/sepsis, malignant degeneration, and functional impairment of adjacent structures
Follow-up Tests
- Tissue culture: Obtained simultaneously with biopsy to identify causative organisms and determine antimicrobial susceptibility
- Special staining studies: Acid-fast bacilli (AFB) stain for tuberculosis, fungal stains (PAS, GMS), Gram stain for bacterial identification
- Imaging studies: MRI or CT scan if granulomatous disease suspected to evaluate for systemic involvement or additional foci
- Tuberculosis testing: Chest X-ray, TB culture, and interferon-gamma release assay if tuberculous fistula suspected
- Serology/serum markers: ACE level and chest imaging if sarcoidosis suspected; inflammatory markers (CRP, ESR) for inflammatory conditions
- Immunohistochemical staining: May be performed for better characterization of inflammatory infiltrate or confirmation of malignancy
- Surgical consultation: For definitive management based on biopsy results; may include fistulotomy, fistulectomy, or other surgical approaches
- Repeat biopsy: If initial specimen is inadequate or if clinical suspicion remains high despite benign findings
- Monitoring frequency: Depends on diagnosis; benign fistulas may be monitored clinically, while malignant or infectious causes require more intensive follow-up
Fasting Required?
- Fasting requirement: No fasting is required for this biopsy procedure
- Medications: Most routine medications can be continued; anticoagulants (warfarin, aspirin, clopidogrel) may need to be held 5-7 days prior with physician approval to minimize bleeding risk
- Patient preparation: Cleansing of the biopsy site may be performed with antiseptic solution; local anesthesia (lidocaine or similar) is typically administered
- Procedural considerations: Sterile technique is essential; patient should avoid heavy activity for 24-48 hours post-procedure to prevent bleeding or wound complications
- Wound care: Keep biopsy site clean and dry; apply dressing as instructed; watch for signs of infection such as increased pain, redness, swelling, or purulent drainage
- Specimen handling: Tissue must be promptly placed in appropriate fixative (usually formalin) and labeled correctly for histopathological processing

How our test process works!